GCP
TPTX

GSA Capital Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

GSA Capital Partners’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,319
Closed -$416K – 1266
2020
Q1 		$416K Buy
9,319
+5,973
+179% +$317K 0.1% 268
2019
Q4 		$208K Buy
+3,346
New +$159K 0.02% 1238

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

GSA Capital Partners's TPTX Position: Q2 2020 in Review

GSA Capital Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2020, closing a stake of 9,319 shares — an estimated $416K sold.

GSA Capital Partners first reported a position in TPTX in Q4 2019 and held it in 2 quarters. The position peaked at $416K in Q1 2020. 158 funds tracked by Wall St. Rank hold TPTX as of Q2 2020.

  • GSA Capital Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • GSA Capital Partners sold 9,319 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $416K.
  • GSA Capital Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • GSA Capital Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $416K in Q1 2020.
  • 158 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2020.

Based on GSA Capital Partners's 13F filing for Q2 2020, filed 11 Aug 2020.